BioCentury
ARTICLE | Politics & Policy

Drug price hikes would have been impossible under pending bipartisan legislation backed by White House, Democrats

January 2, 2020 10:46 PM UTC

The latest round of increases in the list prices of drugs highlights how pending bipartisan legislation could force biopharma companies to rethink their business models.

In what has become a predictable biannual event, manufacturers announced price increases on hundreds of drugs this week. The average increase was 5.8%, according to Rx Savings Solutions...